NCT02763644View on ClinicalTrials.gov

Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 22, 2016

Primary Completion Date

February 10, 2017

Study Completion Date

June 30, 2017

Conditions
Transplant Associated Microangiopathy TAM
Interventions
DRUG

LFG316 active drug

LFG316

OTHER

Standard of care treatment

SoC (site specific)

Trial Locations (6)

13273

Novartis Investigative Site, Marseille

20246

Novartis Investigative Site, Hamburg

27599

Novartis Investigative Site, Chapel Hill

43210

Novartis Investigative Site, Columbus

69120

Novartis Investigative Site, Heidelberg

75475

Novartis Investigative Site, Paris

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY